NORDIC NANOVECTOR CAPITAL MARKETS DAY 2015: REITERATES ITS COMMITMENT TO BECOMING A SIGNIFICANT PLAYER IN ONCOLOGY AND HEMATOLOGY
Oslo, Norway, 18 November 2015
On 17 November 2015, Nordic Nanovector ASA (OSE: NANO) hosted its first Capital Markets Day in Oslo to provide investors, analysts and press with the opportunity to learn more about the Company’s corporate strategy, its lead product Betalutin®, a potential new treatment for non-Hodgkin’s lymphoma (NHL), its development and commercialisation plans, as well as future opportunities for value creation.
The presentations are available at www.nordicnanovector.com in the section:
Investor Relations/Reports and Presentations/Capital Markets Day 2015.
NHL represents a substantial unmet need
The market opportunity for the treatment of patients with NHL is significant. It is estimated to exceed USD 12 billion by 2018. NHL is the tenth most common type of cancer and the third fastest growing cancer on a global basis. Approximately 1.5 million people worldwide are living with NHL, and an estimated 300,000 people die each year from the disease. Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the primary targets for Betalutin®. These are the most common forms of NHL being responsible for more than half of NHL cases. The disease is usually not curable in advanced stages. Alternative therapies for NHL today, include chemotherapy, immunotherapy, radiotherapy and other targeted treatments. Although a substantial number of patients can be cured by these treatments, many become refractory and relapse, or refuse chemotherapy, indicating a clear unmet need for new therapeutic options.
Betalutin® is specifically designed to deliver better treatment outcomes for NHL patients
Promising data from pre-clinical and clinical studies with Betalutin® in NHL patients were recently presented at the 13th ICML in Lugano. In this ongoing Phase 1/2 clinical trial, Betalutin has shown an overall response rate of 64% and a complete response of 36% with a predictable, reversible and manageable side effect profile. One of the key features of Betalutin®, an Antibody- Radionuclide-Conjugate (ARC), is its ability to target and selectively kill tumour cells by delivering a radioactive payload directly to cancer cells and to the local tumour environment. Betalutin®’s unique value proposition, to physicians and patients, is its efficacy, safety profile, cost efficiency and the improved quality of life it delivers. Betalutin®’s differentiating features include it is one-time therapy, its potential for higher levels of complete response and duration of response, lower discontinuation rates as a result of adverse events and potential synergies when administered with CD20 antibodies.
Nordic Nanovector has established a strong clinical development plan for Betalutin®
The plan targets first regulatory submission for Betalutin®, initially as a 3rd line treatment for patients with follicular lymphoma (FL), in the first half of 2019. The recently updated clinical development program will increase the probability of achieving or possibly exceeding the competitive and attractive target product profile for this indication. A range of protective pre-dosing regimens are being evaluated in the ongoing Phase 1/2 study to ensure the optimal pre-dosing and treatment regimen is used in the pivotal Phase 2 PARADIGME study, which is intended to form the basis of the regulatory submission for 3rd line FL.
An encouraging pipeline of projects
A comprehensive development plan is in place to capture Betalutin’s potential beyond the initial target indication of 3rd line FL and includes 2nd line FL, DLBCL, other B-cell tumors as well as multiple myeloma.
Nordic Nanovector’s strategy is focused on maximizing shareholder value
The Company’s key strategic objectives are:
• Obtaining approval for Betalutin in 3rd line FL and 2nd line FL
• Extending the indications for Betalutin to include DLBCL as soon as possible
• Selectively extending the Company’s pipeline around its core expertise (ARC and haematology) to enhance innovation and manage risk
• Independently commercializing Betalutin and its pipeline products/indications in major markets
• Taking an opportunistic approach to partnership opportunities to leverage the potential of its product pipeline and core expertise
###
For further information, please contact:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
ir@nordicnanovector.com
Tel: +47 22 18 33 01
Cell: +47 91 51 95 76
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
nordicnanovector@citigatedr.co.uk
Tel: +44 207 282 2948/+44 207 282 2949
About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
Tags: